Physician profile
Gregory E Buck
NPI 1144269861
$5,728.48
in general payments reported to CMS, 2019-2025
40 companies · $1,056 in 2025
The $1,056 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,980 · 2020: $456 · 2021: $47.14 · 2023: $1,220 · 2024: $970 · 2025: $1,056.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,166 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,166.09 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $865.13 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $857.14 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $520.96 | 2019-2025 | |
| Abbvie INC. | $345.65 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Lilly USA, LLC | $325.93 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $292.01 | 2019-2025 | Repatha |
| Glaxosmithkline, LLC. | $254.39 | 2019-2025 | Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $249.68 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Janssen Pharmaceuticals, INC | $164.85 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $161.81 | 2023-2025 | |
| Sanofi-Aventis U.S. LLC | $148.16 | 2019-2023 | |
| Astellas Pharma US INC | $147.01 | 2019-2023 | Veozah |
| Allergan, INC. | $134.87 | 2019 | |
| Novartis Pharmaceuticals Corporation | $129.26 | 2019-2023 | |
| Aimmune Therapeutics, INC. | $125.00 | 2024 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $86.08 | 2019-2025 | Verquvo, Belsomra, Gardasil 9 |
| Exact Sciences Corporation | $84.77 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Axsome Therapeutics, INC. | $75.33 | 2024-2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $74.67 | 2023-2025 | Caplyta |
| Abbott Laboratories | $65.25 | 2024-2025 | Freestyle Libre 3 |
| Sumitomo Pharma America, INC. | $64.15 | 2023-2024 | Gemtesa |
| Takeda Pharmaceuticals U.S.A., INC. | $60.92 | 2019-2023 | Trintellix |
| Genentech USA, INC. | $60.45 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $60.20 | 2019-2020 | |
| Dexcom, INC. | $51.54 | 2023-2025 | Dexcom G6 Transmitter |
| Lundbeck LLC | $38.64 | 2023 | Rexulti |
| Medtronic, INC. | $28.86 | 2025 | Concertotm |
| Cumberland Pharmaceuticals, INC. | $27.55 | 2025 | Vibativ |
| Ironshore Pharmaceuticals INC. | $26.22 | 2019 | |
| Sunovion Pharmaceuticals INC. | $24.28 | 2019 | |
| Radius Health, INC. | $23.73 | 2025 | |
| Insulet Corporation | $20.81 | 2024 | Omnipod |
| Avanir Pharmaceuticals, INC. | $19.74 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $19.60 | 2019 | |
| Amarin Pharma, INC. | $18.84 | 2020 | |
| Ibsa Pharma INC. | $16.50 | 2020 | |
| Seqirus USA INC | $15.38 | 2025 | Flucelvax, Fluad |
| Supernus Pharmaceuticals, INC. | $14.98 | 2024 | Qelbree |
| Mylan Specialty L.P. | $14.77 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $13.37 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Buck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.